Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Access barriers and treatment patterns in Philadelphia-negative myeloproliferative neoplasms (Ph- MPN): Insights from a brazilian physician survey

View Full Paper
Ask AI
Bookmark
Share

Authors

RDRuddy DalfeorMGMariana Guaraná

Discussion

Loading...

Member takes

Overview

National survey reveals gaps in diagnostic access for blood disorders among Brazilian hematologists, suggesting the need for improvements.

Key Points

  • To assess the current practices and challenges in managing patients with Philadelphia-negative myeloproliferative neoplasms among Brazilian hematologists.
  • Distributed a digital survey with 31 questions to Brazilian hematologists between March and July 2025.
  • Collected data on physician profiles, diagnostic procedures, and treatment decisions.
  • Analyzed responses from 128 hematologists.
  • 69% reported not having a dedicated Ph- MPN outpatient clinic.
  • 27% lacked access to CALR and MPL testing, while 60% reported no access to next-generation sequencing.
  • 79% of physicians considered allogeneic stem cell transplantation for high-risk MF patients.

Cite This Study

Dalfeor et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6bfhttps://doi.org/10.1182/blood-2025-7356
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Diagnostic conformity to who criteria and use of cytoreductive therapy in classical myeloproliferative neoplasms: Experience from a resource-limited country2025
  2. 2A Single Center’s Experience in the Diagnosis and Treatment of Myeloproliferative Neoplasms2025
  3. 3Discrepancies in Treatment Goals and Concerns Regarding Disease Management between Patients with Myeloproliferative Neoplasms and Hematologists in China: Analysis from a Multicenter Cross-Sectional Survey2025
  4. 4Global assessment of patient and caregiver unmet needs in myeloproliferative neoplasms (MPNs): Findings from the 2024 international assessment2025
  5. 5Myeloproliferative neoplasms in Mexico: An analysis of clinical features, driver mutations, and disease progression patterns in a case series.2025